Christoph Ratswohl
Research Subjects
Christoph Ratswohl has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Clara Vázquez García
Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
3 shared publications - Kathrin de la Rosa
Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
3 shared publications - Mikhail Lebedin
Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
3 shared publications - Julia Christine Gutjahr
Faculty of Medicine and Dentistry, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom
2 shared publications - Alexander Egle
Cancer Research Laboratory of the 3rd Medical University Department for Hematology, Medical Oncology, Hemostaseology, Infectious Disease and Rheumatology, Paracelsus Medical University, Salzburg, Austria
1 shared publication Alexey N. Davydov
Central European Institute of Technology, Masaryk University, 601 77 Brno, Czech Republic
1 shared publication
Latest Publications
- Open Access
- 4 June 2026
- Vol. 9 (8)
A “scan and stop” assay identifies CD40 and CD70 as selective regulators of T-cell arrest on APCs
A live-cell assay reveals that CD40 and CD70 selectively promote the arrest of CD4+ and CD8+ T cells on antigen-presenting cells, uncovering a novel function for co-stimulatory molecules.
- 4 June 2026
- Vol. 9 (8)
Open AccessA “scan and stop” assay identifies CD40 and CD70 as selective regulators of T-cell arrest on APCs
A live-cell assay reveals that CD40 and CD70 selectively promote the arrest of CD4+ and CD8+ T cells on antigen-presenting cells, uncovering a novel function for co-stimulatory molecules.
- Open Access
- 19 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1)
Recombination junctions from antibody isotype switching classify immune and DNA repair dysfunction
Personalized assessment of immunocompetence and DNA double-strand break (DSB) repair requires methods that are sensitive to genetic and molecular complexity beyond the well-known monogenic disorders. Inspired by decades of research using B cells to study DNA repair processes, here we present SWIBRID (SWItch junction Breakpoint Repertoire IDentification), a tool to systematically profile genomic junctions generated in vivo during antibody class switch recombination (CSR) in B cells. As CSR junctions reflect immune diversity and DNA repair proficiency, SWIBRID detects phenotypic manifestations of deficiencies via a highly scalable, blood-based PCR followed by long-read sequencing and bioinformatic analysis. We show that specific DNA repair defects, including cancer-associated mutations, exhibit distinct CSR junction patterns. Notably, SWIBRID distinguishes different types of DSB repair knockouts and identifies the respective genetic defect in cell lines. In 68 patients, we detect immunodeficiencies and DNA repair defects with high accuracy (area under the curve 0.99 and 0.84, respectively), and identify previously uncharacterized patient groups as well as patient-specific CSR junction signatures. With SWIBRID, we seek to advance the identification of pathogenic defects, support early diagnosis, and address molecular heterogeneity that drives variable clinical outcomes.
- 19 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1)
Open AccessRecombination junctions from antibody isotype switching classify immune and DNA repair dysfunction
Personalized assessment of immunocompetence and DNA double-strand break (DSB) repair requires methods that are sensitive to genetic and molecular complexity beyond the well-known monogenic disorders. Inspired by decades of research using B cells to study DNA repair processes, here we present SWIBRID (SWItch junction Breakpoint Repertoire IDentification), a tool to systematically profile genomic junctions generated in vivo during antibody class switch recombination (CSR) in B cells. As CSR junctions reflect immune diversity and DNA repair proficiency, SWIBRID detects phenotypic manifestations of deficiencies via a highly scalable, blood-based PCR followed by long-read sequencing and bioinformatic analysis. We show that specific DNA repair defects, including cancer-associated mutations, exhibit distinct CSR junction patterns. Notably, SWIBRID distinguishes different types of DSB repair knockouts and identifies the respective genetic defect in cell lines. In 68 patients, we detect immunodeficiencies and DNA repair defects with high accuracy (area under the curve 0.99 and 0.84, respectively), and identify previously uncharacterized patient groups as well as patient-specific CSR junction signatures. With SWIBRID, we seek to advance the identification of pathogenic defects, support early diagnosis, and address molecular heterogeneity that drives variable clinical outcomes.
- 17 June 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 18 (891) , eadt2678
Intracellular and nuclear CXCR4 signaling promotes terminal erythroblast differentiation and enucleation
The chemokine CXCL12 signals through its receptor CXCR4 to induce the migration of all leukocyte types and multiple other cell types. Here, we report that CXCR4 is expressed in mouse erythroblasts, the bone marrow erythroid precursors, in which it stimulates erythrocyte generation instead of chemotaxis. CXCR4 signaling promoted homeostatic erythroblast maturation and increased the expression of genes mainly involved in metabolism and chromatin organization. Consequently, genetic depletion of CXCR4 in erythroblasts inhibited late erythropoiesis and diminished bone marrow erythroid outputs. Binding of CXCL12 to CXCR4 stimulated its rapid endocytosis and translocation together with Gα i or phosphorylated β-arrestin1 into distinct intracellular compartments, including the nuclear envelope and nucleus. CXCL12 signaling promoted erythroblast elongation and the condensation and excentric positioning of nuclei and stimulated rapid perinuclear Ca 2+ transients that immediately preceded erythroblast enucleation. These findings highlight previously uncharacterized physiological roles for CXCR4 and bone marrow–derived CXCL12 in erythropoiesis.
- 17 June 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 18 (891) , eadt2678
Intracellular and nuclear CXCR4 signaling promotes terminal erythroblast differentiation and enucleation
The chemokine CXCL12 signals through its receptor CXCR4 to induce the migration of all leukocyte types and multiple other cell types. Here, we report that CXCR4 is expressed in mouse erythroblasts, the bone marrow erythroid precursors, in which it stimulates erythrocyte generation instead of chemotaxis. CXCR4 signaling promoted homeostatic erythroblast maturation and increased the expression of genes mainly involved in metabolism and chromatin organization. Consequently, genetic depletion of CXCR4 in erythroblasts inhibited late erythropoiesis and diminished bone marrow erythroid outputs. Binding of CXCL12 to CXCR4 stimulated its rapid endocytosis and translocation together with Gα i or phosphorylated β-arrestin1 into distinct intracellular compartments, including the nuclear envelope and nucleus. CXCL12 signaling promoted erythroblast elongation and the condensation and excentric positioning of nuclei and stimulated rapid perinuclear Ca 2+ transients that immediately preceded erythroblast enucleation. These findings highlight previously uncharacterized physiological roles for CXCR4 and bone marrow–derived CXCL12 in erythropoiesis.
- Open Access
- 23 July 2023
- Published by Wiley in European Journal of Immunology
- Vol. 53 (10) , e2350408
A design strategy to generate a SARS‐CoV‐2 RBD vaccine that abrogates ACE2 binding and improves neutralizing antibody responses
The structure‐based design of antigens holds promise for developing vaccines with higher efficacy and improved safety profiles. We postulate that abrogation of host receptor interaction bears potential for the improvement of vaccines by preventing antigen‐induced modification of receptor function as well as the displacement or masking of the immunogen. Antigen modifications may yet destroy epitopes crucial for antibody neutralization. Here, we present a methodology that integrates deep mutational scans to identify and score SARS‐CoV‐2 receptor binding domain variants that maintain immunogenicity, but lack interaction with the widely expressed host receptor. Single point mutations were scored in silico, validated in vitro, and applied in vivo. Our top‐scoring variant receptor binding domain‐G502E prevented spike‐induced cell‐to‐cell fusion, receptor internalization, and improved neutralizing antibody responses by 3.3‐fold in rabbit immunizations. We name our strategy BIBAX for body‐inert, B‐cell‐activating vaccines, which in the future may be applied beyond SARS‐CoV‐2 for the improvement of vaccines by design.
- 23 July 2023
- Published by Wiley in European Journal of Immunology
- Vol. 53 (10) , e2350408
Open AccessA design strategy to generate a SARS‐CoV‐2 RBD vaccine that abrogates ACE2 binding and improves neutralizing antibody responses
The structure‐based design of antigens holds promise for developing vaccines with higher efficacy and improved safety profiles. We postulate that abrogation of host receptor interaction bears potential for the improvement of vaccines by preventing antigen‐induced modification of receptor function as well as the displacement or masking of the immunogen. Antigen modifications may yet destroy epitopes crucial for antibody neutralization. Here, we present a methodology that integrates deep mutational scans to identify and score SARS‐CoV‐2 receptor binding domain variants that maintain immunogenicity, but lack interaction with the widely expressed host receptor. Single point mutations were scored in silico, validated in vitro, and applied in vivo. Our top‐scoring variant receptor binding domain‐G502E prevented spike‐induced cell‐to‐cell fusion, receptor internalization, and improved neutralizing antibody responses by 3.3‐fold in rabbit immunizations. We name our strategy BIBAX for body‐inert, B‐cell‐activating vaccines, which in the future may be applied beyond SARS‐CoV‐2 for the improvement of vaccines by design.
- Open Access
- 29 August 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (36)
Different classes of genomic inserts contribute to human antibody diversity
Recombination of antibody genes in B cells can involve distant genomic loci and contribute a foreign antigen-binding element to form hybrid antibodies with broad reactivity forPlasmodium falciparum. So far, antibodies containing the extracellular domain of the LAIR1 and LILRB1 receptors represent unique examples of cross-chromosomal antibody diversification. Here, we devise a technique to profile non-VDJ elements from distant genes in antibody transcripts. Independent of the preexposure of donors to malaria parasites, non-VDJ inserts were detected in 80% of individuals at frequencies of 1 in 104to 105B cells. We detected insertions in heavy, but not in light chain or T cell receptor transcripts. We classify the insertions into four types depending on the insert origin and destination: 1) mitochondrial and 2) nuclear DNA inserts integrated at VDJ junctions; 3) inserts originating from telomere proximal genes; and 4) fragile sites incorporated between J-to-constant junctions. The latter class of inserts was exclusively found in memory and in in vitro activated B cells, while all other classes were already detected in naïve B cells. More than 10% of inserts preserved the reading frame, including transcripts with signs of antigen-driven affinity maturation. Collectively, our study unravels a mechanism of antibody diversification that is layered on the classical V(D)J and switch recombination.
- 29 August 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (36)
Open AccessDifferent classes of genomic inserts contribute to human antibody diversity
Recombination of antibody genes in B cells can involve distant genomic loci and contribute a foreign antigen-binding element to form hybrid antibodies with broad reactivity forPlasmodium falciparum. So far, antibodies containing the extracellular domain of the LAIR1 and LILRB1 receptors represent unique examples of cross-chromosomal antibody diversification. Here, we devise a technique to profile non-VDJ elements from distant genes in antibody transcripts. Independent of the preexposure of donors to malaria parasites, non-VDJ inserts were detected in 80% of individuals at frequencies of 1 in 104to 105B cells. We detected insertions in heavy, but not in light chain or T cell receptor transcripts. We classify the insertions into four types depending on the insert origin and destination: 1) mitochondrial and 2) nuclear DNA inserts integrated at VDJ junctions; 3) inserts originating from telomere proximal genes; and 4) fragile sites incorporated between J-to-constant junctions. The latter class of inserts was exclusively found in memory and in in vitro activated B cells, while all other classes were already detected in naïve B cells. More than 10% of inserts preserved the reading frame, including transcripts with signs of antigen-driven affinity maturation. Collectively, our study unravels a mechanism of antibody diversification that is layered on the classical V(D)J and switch recombination.
- Open Access
- 21 September 2017
- Published by Taylor & Francis in OncoImmunology
- Vol. 7 (1) , e1371399
TIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia
While research on T cell exhaustion in context of cancer particularly focuses on CD8+ cytotoxic T cells, the role of inhibitory receptors on CD4+ T-helper cells have remained largely unexplored. TIGIT is a recently identified inhibitory receptor on T cells and natural killer (NK) cells. In this study, we examined TIGIT expression on T cell subsets from CLL patients. While we did not observe any differences in TIGIT expression in CD8+ T cells of healthy controls and CLL cells, we found an enrichment of TIGIT+ T cells in the CD4+ T cell compartment in CLL. Intriguingly, CLL patients with an advanced disease stage displayed elevated numbers of CD4+ TIGIT+ T cells compared to low risk patients. Autologous CLL-T cell co-culture assays revealed that depleting CD4+ TIGIT+ expressing T cells from co-cultures significantly decreased CLL viability. Accordingly, a supportive effect of TIGIT+CD4+ T cells on CLL cells in vitro could be recapitulated by blocking the interaction of TIGIT with its ligands using TIGIT-Fc molecules, which also impeded the T cell specific production of CLL-prosurvival cytokines. Our data reveal that TIGIT+CD4+T cells provide a supportive microenvironment for CLL cells, representing a potential therapeutic target for CLL treatment.
- 21 September 2017
- Published by Taylor & Francis in OncoImmunology
- Vol. 7 (1) , e1371399
Open AccessTIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia
While research on T cell exhaustion in context of cancer particularly focuses on CD8+ cytotoxic T cells, the role of inhibitory receptors on CD4+ T-helper cells have remained largely unexplored. TIGIT is a recently identified inhibitory receptor on T cells and natural killer (NK) cells. In this study, we examined TIGIT expression on T cell subsets from CLL patients. While we did not observe any differences in TIGIT expression in CD8+ T cells of healthy controls and CLL cells, we found an enrichment of TIGIT+ T cells in the CD4+ T cell compartment in CLL. Intriguingly, CLL patients with an advanced disease stage displayed elevated numbers of CD4+ TIGIT+ T cells compared to low risk patients. Autologous CLL-T cell co-culture assays revealed that depleting CD4+ TIGIT+ expressing T cells from co-cultures significantly decreased CLL viability. Accordingly, a supportive effect of TIGIT+CD4+ T cells on CLL cells in vitro could be recapitulated by blocking the interaction of TIGIT with its ligands using TIGIT-Fc molecules, which also impeded the T cell specific production of CLL-prosurvival cytokines. Our data reveal that TIGIT+CD4+T cells provide a supportive microenvironment for CLL cells, representing a potential therapeutic target for CLL treatment.